Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Current Standards of Care for Ph+ Acute Lymphoblastic Leukemia
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemia
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL
May 19th 2023Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.
Read More
On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape
Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
Read More
Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia
Dr Cassaday discusses data supporting the use of combination blinatumomab and pembrolizumab in patients with R/R ALL.
Read More
Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia
Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.
Read More
CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia
Dr Schiller summarizes results from the ZUMA-3 trial and poses thoughtful questions to fellow panelists regarding clinical significance.
Read More
Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Best practices and special considerations for effective therapy selection and sequencing in the relapsed/refractory ALL setting.
Read More
The panelists review highly anticipated results from the E1910 trial assessing combination blinatumomab/consolidation chemotherapy in patients with Philadelphia chromosome-negative ALL.
Read More
Gary J. Schiller, MD and fellow panelists discuss clinical trial outcomes presented at the ASH 2022 annual meeting relevant to patients with Philadelphia chromosome-positive ALL.
Read More
Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia
Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.
Read More
Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia
Ryan Cassaday, MD, notes differences between prognoses for patients with ALL based-on age, subtype, and disease progression status.
Read More
Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia
Armin Ghobadi, MD, and fellow panelists discuss new data concerning patients most at risk for developing ALL.
Read More
Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia
A panel of experts briefly reviews how both pediatric and adult patients with acute lymphoblastic leukemia (ALL) typically present and describes a standard patient workup.
Read More
Differentiating Subtypes of Acute Lymphoblastic Leukemia
Elias Jabbour, MD, leads a discussion on the similarities and differences between ALL subtypes and their respective incidence rates.
Read More
MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL
Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).
Read More
GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL
Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.
Read More
GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL
Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.
Read More
Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL
Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Read More
OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment
Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.
Read More